serial-number stringlengths 7 11 | id stringlengths 7 11 | event stringclasses 2 values | trigger listlengths 1 1 | is-multi-event bool 2 classes | context stringlengths 24 527 | argument-type stringclasses 3 values | role stringclasses 15 values | raw-initial-ground-truth listlengths 1 6 |
|---|---|---|---|---|---|---|---|---|
train-1 | 8908396_3 | adverse_event | [
"induced"
] | false | OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions. | main-arguments | subject | [
"null"
] |
train-2 | 8908396_3 | adverse_event | [
"induced"
] | false | OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions. | main-arguments | treatment | [
"insulin"
] |
train-3 | 8908396_3 | adverse_event | [
"induced"
] | false | OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions. | main-arguments | effect | [
"lipoatrophies"
] |
train-4 | 8908396_3 | adverse_event | [
"induced"
] | false | OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions. | subject | subject-age | [
"null"
] |
train-5 | 8908396_3 | adverse_event | [
"induced"
] | false | OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions. | subject | subject-disorder | [
"null"
] |
train-6 | 8908396_3 | adverse_event | [
"induced"
] | false | OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions. | subject | subject-gender | [
"null"
] |
train-7 | 8908396_3 | adverse_event | [
"induced"
] | false | OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions. | subject | subject-population | [
"null"
] |
train-8 | 8908396_3 | adverse_event | [
"induced"
] | false | OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions. | subject | subject-race | [
"null"
] |
train-9 | 8908396_3 | adverse_event | [
"induced"
] | false | OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions. | treatment | treatment-drug | [
"insulin"
] |
train-10 | 8908396_3 | adverse_event | [
"induced"
] | false | OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions. | treatment | treatment-disorder | [
"diabetic"
] |
train-11 | 8908396_3 | adverse_event | [
"induced"
] | false | OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions. | treatment | treatment-route | [
"null"
] |
train-12 | 8908396_3 | adverse_event | [
"induced"
] | false | OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions. | treatment | treatment-dosage | [
"null"
] |
train-13 | 8908396_3 | adverse_event | [
"induced"
] | false | OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions. | treatment | treatment-time_elasped | [
"null"
] |
train-14 | 8908396_3 | adverse_event | [
"induced"
] | false | OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions. | treatment | treatment-duration | [
"null"
] |
train-15 | 8908396_3 | adverse_event | [
"induced"
] | false | OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the insulin-induced lipoatrophies of a diabetic patient who presented extensive lesions. | treatment | treatment-freq | [
"null"
] |
train-16 | 10891991_1 | adverse_event | [
"develop"
] | false | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment. | main-arguments | subject | [
"women of reproductive age"
] |
train-17 | 10891991_1 | adverse_event | [
"develop"
] | false | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment. | main-arguments | treatment | [
"valproate for epilepsy"
] |
train-18 | 10891991_1 | adverse_event | [
"develop"
] | false | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment. | main-arguments | effect | [
"menstrual cycle disturbances"
] |
train-19 | 10891991_1 | adverse_event | [
"develop"
] | false | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment. | subject | subject-age | [
"reproductive age"
] |
train-20 | 10891991_1 | adverse_event | [
"develop"
] | false | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment. | subject | subject-disorder | [
"epilepsy"
] |
train-21 | 10891991_1 | adverse_event | [
"develop"
] | false | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment. | subject | subject-gender | [
"women"
] |
train-22 | 10891991_1 | adverse_event | [
"develop"
] | false | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment. | subject | subject-population | [
"null"
] |
train-23 | 10891991_1 | adverse_event | [
"develop"
] | false | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment. | subject | subject-race | [
"null"
] |
train-24 | 10891991_1 | adverse_event | [
"develop"
] | false | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment. | treatment | treatment-drug | [
"valproate"
] |
train-25 | 10891991_1 | adverse_event | [
"develop"
] | false | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment. | treatment | treatment-disorder | [
"epilepsy"
] |
train-26 | 10891991_1 | adverse_event | [
"develop"
] | false | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment. | treatment | treatment-route | [
"null"
] |
train-27 | 10891991_1 | adverse_event | [
"develop"
] | false | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment. | treatment | treatment-dosage | [
"null"
] |
train-28 | 10891991_1 | adverse_event | [
"develop"
] | false | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment. | treatment | treatment-time_elasped | [
"null"
] |
train-29 | 10891991_1 | adverse_event | [
"develop"
] | false | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment. | treatment | treatment-duration | [
"null"
] |
train-30 | 10891991_1 | adverse_event | [
"develop"
] | false | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment. | treatment | treatment-freq | [
"null"
] |
train-31 | 2332596_1 | adverse_event | [
"in"
] | false | Phenobarbital hepatotoxicity in an 8-month-old infant. | main-arguments | subject | [
"an 8-month-old infant"
] |
train-32 | 2332596_1 | adverse_event | [
"in"
] | false | Phenobarbital hepatotoxicity in an 8-month-old infant. | main-arguments | treatment | [
"Phenobarbital"
] |
train-33 | 2332596_1 | adverse_event | [
"in"
] | false | Phenobarbital hepatotoxicity in an 8-month-old infant. | main-arguments | effect | [
"hepatotoxicity"
] |
train-34 | 2332596_1 | adverse_event | [
"in"
] | false | Phenobarbital hepatotoxicity in an 8-month-old infant. | subject | subject-age | [
"8-month-old infant"
] |
train-35 | 2332596_1 | adverse_event | [
"in"
] | false | Phenobarbital hepatotoxicity in an 8-month-old infant. | subject | subject-disorder | [
"null"
] |
train-36 | 2332596_1 | adverse_event | [
"in"
] | false | Phenobarbital hepatotoxicity in an 8-month-old infant. | subject | subject-gender | [
"null"
] |
train-37 | 2332596_1 | adverse_event | [
"in"
] | false | Phenobarbital hepatotoxicity in an 8-month-old infant. | subject | subject-population | [
"null"
] |
train-38 | 2332596_1 | adverse_event | [
"in"
] | false | Phenobarbital hepatotoxicity in an 8-month-old infant. | subject | subject-race | [
"null"
] |
train-39 | 2332596_1 | adverse_event | [
"in"
] | false | Phenobarbital hepatotoxicity in an 8-month-old infant. | treatment | treatment-drug | [
"Phenobarbital"
] |
train-40 | 2332596_1 | adverse_event | [
"in"
] | false | Phenobarbital hepatotoxicity in an 8-month-old infant. | treatment | treatment-disorder | [
"null"
] |
train-41 | 2332596_1 | adverse_event | [
"in"
] | false | Phenobarbital hepatotoxicity in an 8-month-old infant. | treatment | treatment-route | [
"null"
] |
train-42 | 2332596_1 | adverse_event | [
"in"
] | false | Phenobarbital hepatotoxicity in an 8-month-old infant. | treatment | treatment-dosage | [
"null"
] |
train-43 | 2332596_1 | adverse_event | [
"in"
] | false | Phenobarbital hepatotoxicity in an 8-month-old infant. | treatment | treatment-time_elasped | [
"null"
] |
train-44 | 2332596_1 | adverse_event | [
"in"
] | false | Phenobarbital hepatotoxicity in an 8-month-old infant. | treatment | treatment-duration | [
"null"
] |
train-45 | 2332596_1 | adverse_event | [
"in"
] | false | Phenobarbital hepatotoxicity in an 8-month-old infant. | treatment | treatment-freq | [
"null"
] |
train-46 | 12552054_1 | adverse_event | [
"following"
] | true | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. | main-arguments | subject | [
"null"
] |
train-47 | 12552054_1 | adverse_event | [
"following"
] | true | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. | main-arguments | treatment | [
"intrathecal methotrexate and cytarabine"
] |
train-48 | 12552054_1 | adverse_event | [
"following"
] | true | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. | main-arguments | effect | [
"Balint syndrome with irreversible posterior leukoencephalopathy on MRI"
] |
train-49 | 12552054_1 | adverse_event | [
"following"
] | true | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. | subject | subject-age | [
"null"
] |
train-50 | 12552054_1 | adverse_event | [
"following"
] | true | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. | subject | subject-disorder | [
"null"
] |
train-51 | 12552054_1 | adverse_event | [
"following"
] | true | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. | subject | subject-gender | [
"null"
] |
train-52 | 12552054_1 | adverse_event | [
"following"
] | true | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. | subject | subject-population | [
"null"
] |
train-53 | 12552054_1 | adverse_event | [
"following"
] | true | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. | subject | subject-race | [
"null"
] |
train-54 | 12552054_1 | adverse_event | [
"following"
] | true | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. | treatment | treatment-drug | [
"methotrexate",
"cytarabine"
] |
train-55 | 12552054_1 | adverse_event | [
"following"
] | true | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. | treatment | treatment-disorder | [
"null"
] |
train-56 | 12552054_1 | adverse_event | [
"following"
] | true | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. | treatment | treatment-route | [
"intrathecal"
] |
train-57 | 12552054_1 | adverse_event | [
"following"
] | true | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. | treatment | treatment-dosage | [
"null"
] |
train-58 | 12552054_1 | adverse_event | [
"following"
] | true | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. | treatment | treatment-time_elasped | [
"null"
] |
train-59 | 12552054_1 | adverse_event | [
"following"
] | true | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. | treatment | treatment-duration | [
"null"
] |
train-60 | 12552054_1 | adverse_event | [
"following"
] | true | The authors report a case of Balint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and cytarabine. | treatment | treatment-freq | [
"null"
] |
train-61 | 19531695_12 | adverse_event | [
"cause"
] | true | According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. | main-arguments | subject | [
"the patient"
] |
train-62 | 19531695_12 | adverse_event | [
"cause"
] | true | According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. | main-arguments | treatment | [
"flecainide"
] |
train-63 | 19531695_12 | adverse_event | [
"cause"
] | true | According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. | main-arguments | effect | [
"delirium"
] |
train-64 | 19531695_12 | adverse_event | [
"cause"
] | true | According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. | subject | subject-age | [
"null"
] |
train-65 | 19531695_12 | adverse_event | [
"cause"
] | true | According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. | subject | subject-disorder | [
"null"
] |
train-66 | 19531695_12 | adverse_event | [
"cause"
] | true | According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. | subject | subject-gender | [
"null"
] |
train-67 | 19531695_12 | adverse_event | [
"cause"
] | true | According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. | subject | subject-population | [
"null"
] |
train-68 | 19531695_12 | adverse_event | [
"cause"
] | true | According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. | subject | subject-race | [
"null"
] |
train-69 | 19531695_12 | adverse_event | [
"cause"
] | true | According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. | treatment | treatment-drug | [
"flecainide",
"flecainide",
"paroxetine"
] |
train-70 | 19531695_12 | adverse_event | [
"cause"
] | true | According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. | treatment | treatment-disorder | [
"null"
] |
train-71 | 19531695_12 | adverse_event | [
"cause"
] | true | According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. | treatment | treatment-route | [
"null"
] |
train-72 | 19531695_12 | adverse_event | [
"cause"
] | true | According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. | treatment | treatment-dosage | [
"null"
] |
train-73 | 19531695_12 | adverse_event | [
"cause"
] | true | According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. | treatment | treatment-time_elasped | [
"null"
] |
train-74 | 19531695_12 | adverse_event | [
"cause"
] | true | According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. | treatment | treatment-duration | [
"null"
] |
train-75 | 19531695_12 | adverse_event | [
"cause"
] | true | According to the Naranjo probability scale, flecainide was the probable cause of the patient's delirium; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine. | treatment | treatment-freq | [
"null"
] |
train-76 | 8002140_2 | adverse_event | [
"due"
] | false | Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature. | main-arguments | subject | [
"null"
] |
train-77 | 8002140_2 | adverse_event | [
"due"
] | false | Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature. | main-arguments | treatment | [
"budesonide"
] |
train-78 | 8002140_2 | adverse_event | [
"due"
] | false | Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature. | main-arguments | effect | [
"Contact dermatitis"
] |
train-79 | 8002140_2 | adverse_event | [
"due"
] | false | Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature. | subject | subject-age | [
"null"
] |
train-80 | 8002140_2 | adverse_event | [
"due"
] | false | Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature. | subject | subject-disorder | [
"null"
] |
train-81 | 8002140_2 | adverse_event | [
"due"
] | false | Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature. | subject | subject-gender | [
"null"
] |
train-82 | 8002140_2 | adverse_event | [
"due"
] | false | Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature. | subject | subject-population | [
"null"
] |
train-83 | 8002140_2 | adverse_event | [
"due"
] | false | Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature. | subject | subject-race | [
"null"
] |
train-84 | 8002140_2 | adverse_event | [
"due"
] | false | Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature. | treatment | treatment-drug | [
"budesonide"
] |
train-85 | 8002140_2 | adverse_event | [
"due"
] | false | Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature. | treatment | treatment-disorder | [
"null"
] |
train-86 | 8002140_2 | adverse_event | [
"due"
] | false | Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature. | treatment | treatment-route | [
"null"
] |
train-87 | 8002140_2 | adverse_event | [
"due"
] | false | Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature. | treatment | treatment-dosage | [
"null"
] |
train-88 | 8002140_2 | adverse_event | [
"due"
] | false | Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature. | treatment | treatment-time_elasped | [
"null"
] |
train-89 | 8002140_2 | adverse_event | [
"due"
] | false | Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature. | treatment | treatment-duration | [
"null"
] |
train-90 | 8002140_2 | adverse_event | [
"due"
] | false | Contact dermatitis due to budesonide: report of five cases and review of the Japanese literature. | treatment | treatment-freq | [
"null"
] |
train-91 | 8586895_3 | adverse_event | [
"following"
] | false | Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine. | main-arguments | subject | [
"a Japanese patient with vivax malaria"
] |
train-92 | 8586895_3 | adverse_event | [
"following"
] | false | Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine. | main-arguments | treatment | [
"halofantrine"
] |
train-93 | 8586895_3 | adverse_event | [
"following"
] | false | Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine. | main-arguments | effect | [
"Prolongation of the QT interval"
] |
train-94 | 8586895_3 | adverse_event | [
"following"
] | false | Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine. | subject | subject-age | [
"null"
] |
train-95 | 8586895_3 | adverse_event | [
"following"
] | false | Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine. | subject | subject-disorder | [
"vivax malaria"
] |
train-96 | 8586895_3 | adverse_event | [
"following"
] | false | Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine. | subject | subject-gender | [
"null"
] |
train-97 | 8586895_3 | adverse_event | [
"following"
] | false | Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine. | subject | subject-population | [
"null"
] |
train-98 | 8586895_3 | adverse_event | [
"following"
] | false | Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine. | subject | subject-race | [
"Japanese"
] |
train-99 | 8586895_3 | adverse_event | [
"following"
] | false | Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine. | treatment | treatment-drug | [
"halofantrine"
] |
train-100 | 8586895_3 | adverse_event | [
"following"
] | false | Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine. | treatment | treatment-disorder | [
"vivax malaria"
] |
End of preview. Expand
in Data Studio
README.md exists but content is empty.
- Downloads last month
- 20